Literature DB >> 31641191

Comparison of minimal residual disease levels in bone marrow and peripheral blood in adult acute lymphoblastic leukemia.

Nicola Gökbuget1, Monika Brüggemann2, Michaela Kotrova3, Antonia Volland3, Britta Kehden3, Heiko Trautmann3, Matthias Ritgen3, Ralph Wäsch4, Christoph Faul5, Andreas Viardot6, Stefan Schwartz7, Claudia D Baldus3.   

Abstract

Entities:  

Mesh:

Year:  2019        PMID: 31641191     DOI: 10.1038/s41375-019-0599-1

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  4 in total

1.  MRD in adult Ph/BCR-ABL-negative ALL: how best to eradicate?

Authors:  Nicola Gökbuget
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

2.  Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia.

Authors:  Lori Muffly; Vandana Sundaram; Connie Chen; Ilana Yurkiewicz; Eric Kuo; Sarah Burnash; Jay Y Spiegel; Sally Arai; Matthew J Frank; Laura J Johnston; Robert Lowsky; Everett H Meyer; Robert S Negrin; Andrew R Rezvani; Surbhi Sidana; Parveen Shiraz; Judith A Shizuru; Wen-Kai Weng; Michaela Liedtke; Hyma T Vempaty; David B Miklos
Journal:  Blood Adv       Date:  2021-08-24

Review 3.  MRD in ALL: Optimization and Innovations.

Authors:  Eric Pierce; Benjamin Mautner; Joseph Mort; Anastassia Blewett; Amy Morris; Michael Keng; Firas El Chaer
Journal:  Curr Hematol Malig Rep       Date:  2022-05-26       Impact factor: 4.213

4.  Consensus Recommendations for MRD Testing in Adult B-Cell Acute Lymphoblastic Leukemia in Ontario.

Authors:  Anne Tierens; Tracy L Stockley; Clinton Campbell; Jill Fulcher; Brian Leber; Elizabeth McCready; Peter J B Sabatini; Bekim Sadikovic; Andre C Schuh
Journal:  Curr Oncol       Date:  2021-03-30       Impact factor: 3.677

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.